/

Empresas

Tr

No verificado

Tris Pharma, Inc.

Sobre qué escribimos

BiotecnologíaFarmacéuticaIndustriaMedicina - VariosSalud

14 Comunicados de prensa

Ver todos los comunicados de prensa

16/10/2025

Ciencia

Psiquiatría

Medicina - Varios

Sanidad

Higiene alimentaria

Biotecnología

Farmacéutica

Salud

Análisis de Mercados

Industria

Tris Pharma Announces Acceptance of New Review Article Highlighting Challenges of Treating Moderate-to-Severe Acute Pain with Currently Available Drugs

Fuente

Tris Pharma, Inc.

Editor

1.00

0

28/08/2025

Salud

Medicina - Varios

Ciencia

Farmacéutica

Biotecnología

Eventos

Finanzas

Industria

Tris Pharma Showcases a Novel Mechanism of Dual-NOP/MOP (NMR) Agonism for the Treatment of Moderate-to-Severe Acute Pain and Encores Positive Phase 3 Data at 2025 Annual PAINWeek Meeting in Las Vegas

Fuente

Tris Pharma, Inc.

Editor

1.00

0

12/06/2025

Psiquiatría

Ciencia

Higiene alimentaria

Medicina - Varios

Biotecnología

Salud

Farmacéutica

Sanidad

Industria

Tris Pharma to Debut Positive Results of Intranasal (Snorting) Human Abuse Potential Study of Cebranopadol, an Investigational First-In-Class Oral Dual-NMR Agonist for the Treatment of Moderate-to-Severe Pain, at the 2025 CPDD Annual Meeting

Fuente

Tris Pharma, Inc.

Editor

1.00

0

01/05/2025

Eventos

Biotecnología

Sanidad

Salud

Farmacéutica

Medicina - Varios

Tris Pharma to Unveil Positive Phase 3 Results including a Strong Safety Profile Showcasing the Potential of Cebranopadol, an Investigational First-in-Class Dual-NMR Agonist for the Treatment of Pain, at the 2025 ASRA Annual Meeting

Fuente

Tris Pharma, Inc.

Editor

1.00

0

01/04/2025

Eventos

Biotecnología

Sanidad

Medicina - Varios

Salud

Farmacéutica

Tris Pharma to Present New Data at AAPM PainConnect Annual Meeting and Showcase Potential of Cebranopadol, a First-in-Class Investigational Dual-NMR Agonist for the Treatment of Pain

Fuente

Tris Pharma, Inc.

Editor

1.00

0

06/03/2025

Tris Pharma Announces Positive Results from ALLEVIATE-2 Phase 3 Pivotal Trial for Cebranopadol, an Investigational First-in-Class Oral Dual-NMR Agonist, for the Treatment of Moderate-to-Severe Acute Pain

Fuente

Tris Pharma, Inc.

Editor

1.00

0

28/01/2025

Tris Pharma Reports Positive Clinical Results of Intranasal Human Abuse Potential Study Indicating Low Abusability of Cebranopadol, an Investigational, First-in-Class Oral Dual-NMR Agonist for the Treatment of Moderate-to-Severe Pain

Fuente

Tris Pharma, Inc.

Editor

1.00

0

22/01/2025

Industria

Oncología

Salud

Medicina - Varios

Farmacéutica

Biotecnología

Tris Pharma Announces Positive Results from ALLEVIATE-1 Phase 3 Clinical Trial of Cebranopadol, an Investigational First-in-Class Oral Dual-NMR Agonist, for the Treatment of Moderate-to-Severe Acute Pain

Fuente

Tris Pharma, Inc.

Editor

1.00

0

19/11/2024

Psiquiatría

Salud

Sanidad

Farmacéutica

Biotecnología

Industria

Tris Pharma Secures Additional ex-US Approvals to Expand Global Availability of Quillivant XR and QuilliChew ER for the Treatment of Attention Deficit Hyperactivity Disorder

Fuente

Tris Pharma, Inc.

Editor

1.00

0

01/10/2024

Industria

Psiquiatría

Salud

Higiene alimentaria

Sanidad

Farmacéutica

Biotecnología

Tris Pharma’s Once-Daily ADHD Medication, ONYDA XR (clonidine hydrochloride) Extended-Release Oral Suspension, Now Available in the United States

Fuente

Tris Pharma, Inc.

Editor

1.00

0

Seguidores

0

Compatibilidad

0